Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489

Participants needed: 250
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SCRI Development Innovations, LLCUpdated: Aug 17, 2026Locations: 34
Eligibility criteria

At least 18 years-of-age at the time of signature of the Informed Consent Form (... [+9]

Small-cell cancer not pulmonary in origin [+35]

Read more
Status: Recruiting

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM). The primary objective of this study is to evaluate the overall incidence of cytokine release syndrome (CRS) during Cycle 1 of elranatamab treatment following a single prophylactic dose of tocilizumab.

Participants needed: 46
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SCRI Development Innovations, LLCUpdated: Aug 11, 2026Locations: 5
Eligibility criteria

Written informed consent, according to institutional guidelines, signed and date... [+25]

History of antitumor therapy as follows, before the first dose of study drug [+27]

Read more
Status: Recruiting

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of this study are to: * Evaluate the efficacy of the combination of fruquintinib + FOLFIRI in the 2nd-line mCRC setting * Evaluate the safety of the combination of fruquintinib + FOLFIRI

Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SCRI Development Innovations, LLCUpdated: Jun 12, 2026Locations: 14
Eligibility criteria

Confirmed mCRC ; histologically documented adenocarcinoma of the colon or rectum... [+4]

Current treatment with other anticancer treatments within 21 days of the first d... [+11]

Read more
Status: Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidomide and daratumumab treatment (Arm B).

Participants needed: 100
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: SCRI Development Innovations, LLCUpdated: Jun 4, 2026Locations: 11
Eligibility criteria

Age >18 years with no upper age limit. [+19]

Diagnosis of primary light chain amyloidosis, POEMS, Waldenstrom's macroglobulin... [+16]

Read more
Status: Recruiting

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SCRI Development Innovations, LLCUpdated: Apr 22, 2026Locations: 17
Eligibility criteria

Be ≥18 years of age (or the higher legal age in the jurisdiction in which the st... [+22]

Has a rapidly progressing disease per investigator assessment. [+44]

Read more
Status: Recruiting

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil

Participants needed: 36
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SCRI Development Innovations, LLCUpdated: Mar 20, 2026Locations: 8
Eligibility criteria

Written informed consent, according to local guidelines, signed and dated by the... [+24]

Any systemic anti-cancer chemotherapy or small molecule, biologic, or hormonal a... [+21]

Read more